Journal
BLOOD
Volume 105, Issue 4, Pages 1383-1395Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2004-07-2909
Keywords
-
Categories
Funding
- NCI NIH HHS [R0-1 CA50945, IP50 CA100707] Funding Source: Medline
- PHS HHS [P0-1 78378] Funding Source: Medline
Ask authors/readers for more resources
Besides its role as an essential regulator of physiologic and pathologic anglogenesis, vascular endothelial growth factor (VEGF) triggers growth, survival, and migration of leukemia and multiple myeloma cells; plays a pivotal role in hematopolesis; inhibits maturation of dendritic cells; and increases osteoclastic bone-resorbing activity as well as osteoclast chemotaxis. Dysregulation of VEGF expression and signaling pathways therefore plays an important role in the pathogenesis and clinical features of hematologic malignancies, in particular multiple myeloma. Direct and indirect targeting of VEGF and its receptors therefore may provide a Potent novel therapeutic approach to overcome resistance to therapies and thereby improve patient outcome. (C) 2005 by The American Society of Hematology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available